For families watching a loved one start addiction treatment for fentanyl dependence, the expectation is that medically supervised treatment will be safe, managed, and effective. A study published in Drug and Alcohol Dependence is challenging one core element of that assumption: standard starting doses of the primary medication treatments for opioid use disorder — methadone and buprenorphine — may not be calibrated for the potency of the fentanyl that many patients are actually using.
The study examined patients with opioid use disorder in Los Angeles — one of the cities with the highest concentration of illicitly manufactured fentanyl — and found that standard dose protocols developed for patients dependent on heroin or pharmaceutical opioids were frequently inadequate for patients who had been using today's high-potency fentanyl. Those patients experienced inadequate symptom control at standard doses, increasing the risk of treatment dropout, return to use, and overdose during the treatment period.
Why This Matters
Methadone and buprenorphine (the active ingredient in Suboxone) are the two most evidence-based medications for opioid use disorder. They work by occupying opioid receptors, reducing cravings, and preventing the extreme highs and withdrawal lows that drive compulsive opioid use. When properly dosed, they are remarkably effective.
The problem is that fentanyl is not heroin. Illicitly manufactured fentanyl as it circulates in major U.S. cities in 2026 can be 50 to 100 times more potent than heroin on a per-unit basis. A patient who was heavily dependent on today's street fentanyl has a receptor tolerance profile that standard dose tables — developed from heroin-era data — may not adequately address.
What We Know So Far
The Drug and Alcohol Dependence study enrolled patients in Los Angeles-area treatment programs and assessed the relationship between fentanyl exposure history and treatment outcomes at standard dose levels. Key findings:
- Patients with documented heavy fentanyl dependence were more likely to experience inadequate symptom control on standard starting doses of methadone and buprenorphine
- Inadequate dose control was associated with higher rates of early treatment dropout
- Treatment programs using individualized dose titration — adjusting doses more rapidly based on patient response — had better early retention
- Naloxone (Narcan) dosing also requires consideration: fentanyl-related overdoses may require multiple doses or higher doses than standard heroin-era protocols assumed
Where the Risk Is Highest
Cities with the highest concentrations of illicitly manufactured fentanyl — where street supply is dominated by fentanyl rather than heroin — include Los Angeles, San Francisco, Philadelphia, Chicago, Seattle, Denver, and Washington D.C. In these cities, treatment programs that have not updated their dose protocols since the pre-fentanyl era may be systematically under-dosing a significant proportion of their patients.
What Doctors and Experts Say
Addiction medicine specialists have known for several years that the transition from heroin to fentanyl as the dominant opioid in most U.S. cities required rethinking dose protocols. The Drug and Alcohol Dependence study provides formal quantitative evidence for that clinical intuition.
"Adequate dosing is not the same as high dosing," addiction medicine specialists emphasize. The goal is to find the dose that controls cravings and prevents withdrawal without over-sedating the patient — and that threshold has shifted upward for many fentanyl-dependent patients.
For buprenorphine specifically, SAMHSA guidelines now recognize higher-dose formulations — including extended-release injectable buprenorphine (Sublocade) — as providing more consistent blood levels for patients who metabolize standard doses too quickly. The American Society of Addiction Medicine (ASAM) is expected to issue updated dosing guidance that reflects the fentanyl-dominated drug supply.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Study type: Observational, clinical population study
- Published in: Drug and Alcohol Dependence
- Population: Opioid use disorder patients in Los Angeles with heavy fentanyl dependence
- What it found: Standard starting doses of methadone and buprenorphine are often inadequate for patients with heavy fentanyl dependence; under-dosing is associated with worse treatment retention
- What it did not prove: An optimal specific dose — individualized titration based on patient response remains the clinical standard
- What it does not mean: That patients should self-adjust medications; dose changes must be supervised by a prescriber
- What readers should know: Families and patients have the right to ask whether their treatment dose is adequate for their specific dependence profile
Who Faces the Greatest Risk?
- Patients beginning treatment who have been using fentanyl heavily and consistently — who have the highest receptor tolerance
- Patients in programs that use standard dose tables without individualizing for fentanyl potency
- Patients who have left treatment previously after experiencing inadequate symptom control
- Anyone who recently survived a fentanyl overdose and is entering treatment — whose fentanyl exposure may have been particularly high-potency
Symptoms and Warning Signs to Watch For
For families monitoring a loved one starting medication treatment:
Signs that dosing may be inadequate:
- Persistent severe cravings despite being on medication
- Visible withdrawal symptoms (yawning, runny nose, muscle aches, agitation, sweating) while on medication
- Difficulty sleeping due to discomfort
- Requests to supplement medication with other substances
- Early dropout from the program
These signs should be communicated to the treatment provider — not accepted as inevitable.
What You Can Do Now
- Ask your treatment provider specifically : "Is my dose calibrated for fentanyl, or for a standard opioid use disorder protocol?"
- Advocate for individualized dose titration — a process where the dose is adjusted based on your specific symptoms, cravings, and response, rather than set according to a standard starting table.
- If you are experiencing inadequate symptom control, tell your provider. You have the right to have your dose adjusted.
- For overdose survivors starting treatment, discuss with your provider whether standard naloxone doses are sufficient given your exposure history. Fentanyl may require additional Narcan doses in reversal.
- Contact SAMHSA's National Helpline at 1-800-662-4357 if you are having difficulty accessing or maintaining appropriate treatment. SAMHSA's Treatment Locator identifies low-cost and no-cost opioid use disorder treatment programs in every state.
Cost and Access: What Patients Should Know
Methadone treatment for opioid use disorder is covered by Medicaid and most state insurance programs. Buprenorphine (Suboxone, Subutex) is covered by most insurance plans and is increasingly available through primary care and telehealth settings. For uninsured patients, SAMHSA's Treatment Locator identifies low-cost and no-cost opioid use disorder treatment programs in every state.
What Happens Next
ASAM and other addiction medicine professional organizations are expected to issue updated dosing guidance that reflects the fentanyl-dominated drug supply. MedicalDaily will report on any guideline updates or formal clinical recommendations related to fentanyl-specific dosing.
The Bottom Line
Standard medication treatment doses for opioid use disorder were developed before fentanyl dominated the U.S. drug supply. For patients with heavy fentanyl dependence in high-potency markets, those doses may not be adequate — and inadequate dosing is one of the most preventable drivers of treatment dropout and overdose death. Families and patients have the right to ask for individualized dose titration that is calibrated for their specific dependence profile.
